Thelansis’s “Interstitial Cystitis (IC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Interstitial cystitis (IC), or bladder pain syndrome, is a chronic disorder causing recurrent pelvic pain, urgency, and frequency without infection, driven by urothelial dysfunction, hyperpermeability, and neurogenic sensitization. Pain characteristically worsens with bladder filling and is relieved by voiding. Diagnosis is clinical, requiring the exclusion of confusable conditions via cystoscopy and culture; a distinct Hunner lesion phenotype requires localized endoscopic identification. Rather than a rigid stepwise ladder, 2026 guidelines mandate a simultaneous, phenotype-directed multimodal strategy. Initial care combines trigger avoidance with pelvic floor physiotherapy. Oral amitriptyline provides systemic relief, while oral pentosan polysulfate is strictly restricted due to irreversible pigmentary maculopathy risks. Intravesical lidocaine or heparin instillations address mucosal symptoms, and Hunner lesions are treated with endoscopic fulguration. Refractory disease utilizes intradetrusor botulinum toxin or sacral neuromodulation.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Interstitial Cystitis (IC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Interstitial Cystitis (IC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.